Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients

Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15–30 days after methylprednisolone administration. Additionally, we propose ACTH, dexa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo de la Cruz, Milagros, Miranda Acuña, Jahir Andrés, Lozano Ros, Alberto, Vega Catalina, María, Salinero Paniagua, Emilio, Clemente Ricote, Gerardo, De Andrés Frutos, Clara Dionisia, Martínez Ginés, María Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538224/
https://www.ncbi.nlm.nih.gov/pubmed/28781825
http://dx.doi.org/10.1002/ccr3.1033
Descripción
Sumario:Hepatotoxicity is a rare adverse event of methylprednisolone that should be considered in clinical practice. In patients at risk, we propose liver function surveillance, by measuring hepatic enzymes concentration 15–30 days after methylprednisolone administration. Additionally, we propose ACTH, dexamethasone, or plasma exchange as alternate treatment options for these patients.

Ejemplares similares